SCHEMBL6135927

SCHEMBL6135927

CN(C(=O)NCCc1cccc(Cc2c(-c3ccc(O)cc3)ccc3cc(O)ccc23)c1)c1ccc(O)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.38
▸ ESR2 Q92731 2/20 0.38
▸ TRPV1 Q8NER1 2/20 0.36
▸ MTNR1A P48039 3/20 0.36
▸ MTNR1B P49286 3/20 0.36
▸ SPR P35270 1/20 0.35
▸ OPRM1 P35372 3/20 0.35
▸ OPRD1 P41143 3/20 0.35
▸ OPRK1 P41145 3/20 0.35
▸ ROCK2 O75116 2/20 0.34
▸ NQO2 P16083 2/20 0.33
▸ ESRRG P62508 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ ROCK1 Q13464 1/20 0.33
▸ ESRRB O95718 1/20 0.32
▸ TLR8 Q9NR97 1/20 0.32
▸ MAOB P27338 1/20 0.32
▸ SNCA P37840 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136267 0.96 OPRM1 (0.40) ESR1ESR2TRPV1MTNR1AMTNR1B
SCHEMBL6136150 0.96 CNR1 (0.39) ESR1ESR2TRPV1MTNR1AMTNR1B
SCHEMBL6136157 0.94 ESR1 (0.40) ESR1ESR2MTNR1AMTNR1BSPR
SCHEMBL6136101 0.84 ESR1 (0.46) ESR1ESR2TRPV1ROCK2MAOB
SCHEMBL6136484 0.82 ESR1 (0.44) ESR1ESR2TRPV1MAOB
SCHEMBL6136126 0.82 TRPV1 (0.47) ESR1ESR2TRPV1ROCK2ROCK1
SCHEMBL6136002 0.81 ESR1 (0.43) ESR1ESR2ROCK2MAPTMAOB
SCHEMBL6136136 0.80 TRPV1 (0.50) TRPV1ROCK2MAPTROCK1
SCHEMBL6136079 0.80 ESR1 (0.42) ESR1ESR2MAOB
SCHEMBL6136383 0.80 NPY5R (0.43) ESR1ESR2TRPV1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback